Journal article
Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC).
Abstract
126
Background: Although abiraterone acetate (AA), a CYP17 inhibitor, increases survival in men with metastatic castration resistant prostate cancer (mCRPC), tumors eventually progress on therapy. The primary purpose of this study was to identify mechanisms of resistance to AA via analysis of the androgen receptor signaling pathway in serial tumor biopsies of men receiving AA and dutasteride (DUT), a type I and II 5-α …
Authors
McKay RR; Werner L; Zukotynski KA; Domachevsky L; Elfiky A; Pomerantz MM; Bubley GJ; Montgomery RB; Kantoff PW; Taplin M-E
Journal
Journal of Clinical Oncology, Vol. 32, No. 4_suppl, pp. 126–126
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2014
DOI
10.1200/jco.2014.32.4_suppl.126
ISSN
0732-183X